Skip to main content
Fig. 2 | BMC Ophthalmology

Fig. 2

From: Comparison of intravitreal preservative-free triamcinolone versus posterior sub-tenon triamcinolone acetonide injection for bevacizumab-resistant diabetic macular edema

Fig. 2

Representative images comparing results of IVTA and posterior STTA injections in patients with bevacizumab-resistant DME. (A) Initial presentation of the left eye of a 59-year-old male patient who showed no response to IVB injections. SD-OCT reveals diffuse retinal thickening and serous retinal detachment associated with diabetic macular edema. (B) Resolution of macular edema and serous retinal detachment at 1 month after IVTA injection. (C) Complete resolution of serous retinal detachment and cystic change at 2 months after treatment. (D) Slight aggravation of serous retinal detachment and macular edema at 3 months after treatment. (E) Initial presentation of the left eye of a 57-year-old male patient who showed no response to IVB injections. SD-OCT shows diffuse retinal thickening and serous retinal detachment associated with diabetic macular edema. (F) Complete resolution of serous retinal detachment and macular edema at 1 month after posterior STTA injection. (G) Sustained macular edema at 2 months after treatment. (H) Slight aggravation of macular edema at 3 months after treatment. DME, diabetic macular edema; IVB, intravitreal bevacizumab; IVTA, intravitreal triamcinolone acetonide; SD-OCT, Spectral-domain optical coherence tomography; STTA, sub-Tenon’s capsule triamcinolone acetonide

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us